Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Medical Equipment Industry Analysis

UpdatedNov 14, 2025
DataAggregated Company Financials
Companies198
  • 7D1.7%
  • 3M1.2%
  • 1Y4.3%
  • YTDn/a

In the last week, the Medical Equipment industry is up 1.7%, with Abbott Laboratories up 3.7%. In the last 12 months, the industry was up 4.3%. As for the next few years, earnings are expected to grow by 12% per annum.

Industry Valuation and Performance

Has the U.S. Medical Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 18 Nov 2025US$1.3tUS$261.6bUS$31.6b31.1x40.9x5x
Thu, 16 Oct 2025US$1.2tUS$257.2bUS$32.8b32.2x37.5x4.8x
Sat, 13 Sep 2025US$1.3tUS$256.4bUS$32.8b32.2x38.8x5x
Mon, 11 Aug 2025US$1.3tUS$255.8bUS$32.7b30.7x38.6x4.9x
Wed, 09 Jul 2025US$1.3tUS$250.7bUS$30.5b33.4x41.7x5.1x
Fri, 06 Jun 2025US$1.3tUS$250.7bUS$30.5b33.8x41.7x5.1x
Sun, 04 May 2025US$1.2tUS$249.8bUS$28.7b32x43.6x5x
Tue, 01 Apr 2025US$1.2tUS$247.3bUS$28.1b31x43.9x5x
Thu, 27 Feb 2025US$1.3tUS$247.2bUS$28.3b34.7x46.6x5.3x
Sat, 25 Jan 2025US$1.3tUS$249.7bUS$30.2b41x43.8x5.3x
Mon, 23 Dec 2024US$1.2tUS$248.5bUS$22.4b36.3x54.1x4.9x
Wed, 20 Nov 2024US$1.2tUS$247.7bUS$21.8b35.9x57x5x
Fri, 18 Oct 2024US$1.2tUS$245.0bUS$20.7b37.5x58.8x5x
Sun, 15 Sep 2024US$1.2tUS$244.6bUS$20.5b38.5x59.6x5x
Tue, 13 Aug 2024US$1.1tUS$244.4bUS$20.2b33.6x56.7x4.7x
Thu, 11 Jul 2024US$1.1tUS$241.6bUS$20.6b35x55.1x4.7x
Sat, 08 Jun 2024US$1.2tUS$241.6bUS$20.6b35.5x56.4x4.8x
Mon, 06 May 2024US$1.2tUS$242.3bUS$22.7b35.3x51x4.8x
Wed, 03 Apr 2024US$1.2tUS$239.9bUS$22.0b38.2x54.6x5x
Fri, 01 Mar 2024US$1.2tUS$240.0bUS$22.0b36.1x53.8x4.9x
Sun, 28 Jan 2024US$1.2tUS$241.8bUS$20.8b34.4x55.8x4.8x
Tue, 26 Dec 2023US$1.1tUS$241.2bUS$19.9b37.1x56.5x4.7x
Thu, 23 Nov 2023US$1.0tUS$241.2bUS$19.9b33.5x52.2x4.3x
Sat, 21 Oct 2023US$979.7bUS$237.9bUS$15.9b32.5x61.7x4.1x
Mon, 18 Sep 2023US$1.1tUS$238.0bUS$15.7b35x68x4.5x
Wed, 16 Aug 2023US$1.1tUS$237.7bUS$15.8b36.6x70.4x4.7x
Fri, 14 Jul 2023US$1.2tUS$235.6bUS$16.7b37.3x71.2x5.1x
Sun, 11 Jun 2023US$1.1tUS$235.6bUS$16.7b35.3x67.3x4.8x
Tue, 09 May 2023US$1.2tUS$235.0bUS$17.2b37.9x68x5x
Thu, 06 Apr 2023US$1.1tUS$234.8bUS$18.9b34.5x58.6x4.7x
Sat, 04 Mar 2023US$1.1tUS$234.8bUS$18.9b38.1x57.5x4.6x
Mon, 30 Jan 2023US$1.1tUS$236.2bUS$19.8b33.1x55x4.6x
Wed, 28 Dec 2022US$1.0tUS$219.4bUS$18.9b29.8x54.4x4.7x
Fri, 25 Nov 2022US$1.0tUS$219.3bUS$19.0b30.7x54.1x4.7x
Price to Earnings Ratio

54.1x


Total Market Cap: US$1.0tTotal Earnings: US$19.0bTotal Revenue: US$219.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Medical Equipment Industry Price to Earnings3Y Average 53.8x202320242025
Current Industry PE
  • Investors are pessimistic on the American Healthcare Equipment industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 40.9x which is lower than its 3-year average PE of 53.8x.
  • The industry is trading close to its 3-year average PS ratio of 4.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Equipment industry have grown 19% per year over the last three years.
  • Revenues for these companies have grown 6.0% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does U.S. Medical Equipment compare with similar industries?

US Market-0.39%
Healthcare3.77%
Medical Equipment1.73%
Medical Equipment1.73%
Medical Supplies1.84%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABT Abbott LaboratoriesUS$130.593.7%
+US$8.2b		11.3%PE16.3x
MDT MedtronicUS$95.873.5%
+US$4.1b		9.5%PE26.4x
BDX Becton DickinsonUS$193.046.3%
+US$3.3b		-13.9%PE33x
SYK StrykerUS$362.222.0%
+US$2.8b		-7.0%PE47.1x
BSX Boston ScientificUS$102.691.8%
+US$2.6b		13.5%PE54.5x

Latest News

RMD
US$244.46
ResMed
7D
-2.3%
1Y
2.1%
BDX
US$193.04
Becton Dickinson
7D
6.3%
1Y
-13.9%

Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Nov 16
Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings
DXCM
US$58.06
DexCom
7D
5.9%
1Y
-23.9%

DXCM: Share Recovery Likely With Positive Setup Expected For 2026

Analysts have lowered their price targets for DexCom, reducing the fair value estimate from $98.40 to $84.96. This reflects a reaction to recent conservative guidance, weaker growth outlook, and updated margin expectations.
IRTC
US$170.82
iRhythm Technologies
7D
-3.1%
1Y
122.2%

IRTC: Future Channel Partnerships Will Drive Continued Market Share Gains

Analysts have raised their price target for iRhythm Technologies from approximately $193 to nearly $220 per share. They cite continued core business strength, expanding Zio AT adoption, and management’s increased confidence in future growth as key factors.
SSII
US$6.22
SS Innovations International
7D
-11.1%
1Y
107.3%

SS Innovations International, Inc.'s (NASDAQ:SSII) 29% Cheaper Price Remains In Tune With Revenues

Nov 14
SS Innovations International, Inc.'s (NASDAQ:SSII) 29% Cheaper Price Remains In Tune With Revenues
TMDX
US$115.01
TransMedics Group
7D
-6.0%
1Y
42.1%

TMDX: Expanding Regulatory Reforms Will Drive U.S. Organ Transplant Opportunity Forward

Analysts have raised their price target for TransMedics Group from $141.91 to a range between $148 and $170, citing stronger-than-expected U.S. sales, rapid margin improvement, and anticipated benefits from regulatory reforms and clinical advancements. Analyst Commentary Recent Street research provides a mixed, but largely positive, outlook on TransMedics Group, highlighting both key growth drivers and areas of potential caution as the company targets an expanding opportunity in organ transplantation.
ABT
US$130.59
Abbott Laboratories
7D
3.7%
1Y
11.3%

ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains

Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.
STE
US$258.41
STERIS
7D
-2.1%
1Y
19.0%
ISRG
US$549.51
Intuitive Surgical
7D
-4.6%
1Y
3.4%
GMED
US$84.45
Globus Medical
7D
-2.2%
1Y
3.2%
EW
US$86.30
Edwards Lifesciences
7D
2.6%
1Y
23.5%

EW: Future Progress Will Hinge On Durable Outcomes And Market Expansion

The analyst price target for Edwards Lifesciences has increased from approximately $88.83 to $93.94. Analysts point to strong quarterly results and sustained momentum in transcatheter aortic valve replacements as key drivers of the upward revision.
IDXX
US$689.93
IDEXX Laboratories
7D
-2.8%
1Y
64.3%
PODD
US$332.70
Insulet
7D
3.9%
1Y
27.6%

Insulet Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 09
Insulet Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
SYK
US$362.22
Stryker
7D
2.0%
1Y
-7.0%
MDT
US$95.87
Medtronic
7D
3.5%
1Y
9.5%

MDT: Focus Will Shift To Board Changes And New Committee Impact

Medtronic's analyst price target has recently increased, with updated targets rising as high as $115. This reflects analysts' growing optimism about the company due to anticipated revenue growth, positive investor engagement, and confidence in its product pipeline and execution.
BSX
US$102.69
Boston Scientific
7D
1.8%
1Y
13.5%

BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence

Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.